Monday, May 28, 2012

10:00 – 5:00 p.m.  Registration  (Curio Foyer)

1:00 – 7:00 p.m.  Interest Group Workshops
Banff Springs Conference Centre – Level 2
(Located across the round-a-bout)

SESSION I  1:00 - 3:00 p.m.  (Baron Shaugnessy)

Interest Group Session: Signaling in Hypertrophy and Failure
Chair: Wally Koch, Jefferson University

Richard Gilbert, Canada: “PKCaß inhibition in the treatment of heart failure”

Tom Force, Temple University: “GSK3 inhibition as an approach to treat heart failure”

Josh Hare, University of Miami: “TNNi3K: A cardiac specific kinase regulating ischemic injury and remodeling”

Joan Heller-Brown, U CSD: “CaMKII signaling in heart failure and development”

SESSION II  1:00 - 3:00 p.m.  (Sir Edward Beatty)

Interest Group Session: Ion Channels and Arrhythmias
Chair: Bjorn Knollmann, Vanderbilt University

Peter Backx, University of Toronto: “NfkB control of transient outward potassium currents in heart failure”

Stephen Archer, University of Chicago: “Metabolic moderation of glucose and fatty acid oxidation as therapy for right heart failure in experimental congenital heart disease and pulmonary hypertension”

Brian O’Rourke, John Hopkins University: “Mitochondrial calcium flux in heart failure”

Steve Houser, Temple University: “The good and the bad of enhanced calcium in the diseased heart”
SESSION III  3:00 – 5:00 p.m.  (D.C. Coleman)

Interest Group Session:  Cardiac Metabolism
Chair: Asa Gustafson, UCSD

Michael Sack, NIH, Bethesda: “Regulation of protein acetylation in the control of mitochondrial homeostasis”

Wang Wang, University of Washington: “Real time measurement of superoxide flash in the heart”

Christine Des Rosiers, University of Montreal: “Post-translational modification of fatty acid uptake proteins?”

Mahesh Gupta, University of Chicago: “Sirtuin involvement in cardiac hypertrophy”

SESSION IV  3:00 - 5:00 p.m.  (Sir Edward Beatty)

Interest Group Session:  Contractile & Regulatory Proteins
Chair: Pieter de Tombe, Loyola University

Michelle Monasky, University of Illinois at Chicago: “Tetrahydrobiopterin improves diastolic myocardial dysfunction concomitant with a reduction in s-glutathionylation of myosin binding protein C.”

Brian Sykes, University of Alberta: “Structural and functional perspective in the mechanisms of myofilament Ca-sensitization.”

Jil Tardiff, University of Arizona: “The role of abnormal Ca\(^{2+}\) handling in hypertrophic cardiomyopathy.”

Beata M. Wolska, University of Illinois at Chicago: “Rescue if hypertrophic and dilated cardiomyopathy mouse models by modulation of the myofilaments response to Ca”

SESSION V  3:00 -5:00 p.m.  (Baron Shaugnessy)

Interest Group Session:  Stem Cell & Gene Therapy
Chair: Chuck Murry, University of Washington

Jun Sadoshima, University of Medicine New Jersey: “GSKB infected stem cells as a therapy for heart failure”

Jay Zhang, University of Minnesota: “Fibrin based patches as a platform for cardiac stem cell delivery”

Tim Kamp, University of Wisconsin: “Human induced pluripotent stem cells and cardiovascular medicine”

Joseph Rabinowitz, Temple University: “AAV targeting of the heart”
SESSION VI  5:00 - 7:00 p.m.  (Sir Edward Beatty)

Interest Group Session: Ischemia, Cardioprotection & Mitochondria
Chair: Charles Steenbergen, John Hopkins

Robbie Gottlieb, San Diego State University: “Autophagy in cardioprotection”

Chris Baines, University of Missouri: “Regulation of the mitochondrial permeability transition pore”

Lorrie Kirschenbaum: University of Manitoba: “BNIP and myocyte survival”

Jim Weiss, University of California, Los Angeles: “Mitochondria and cardioprotection”

SESSION VII  5:00 - 7:00 p.m.  (Baron Shaugnessy)

Interest Group Session: Excitation-Contraction Coupling
Chair: Rick Moss, University of Wisconsin

Litsa Kranias, Cincinnati: “Sarcoplasmic reticulum calcium cycling in heart failure”

Don Bers, University of California Davis: “CaMKII in myocardial hypertrophy and heart failure”

Jon Lederer, University of Maryland: "X-ROS Signaling: Rapid mechano-chemo transduction in heart"  
Marek Michalak, University of Alberta: “Calreticulin and protein quality control in heart failure”

7:00 – 9:00pm Welcome Reception  (Upper / Garden Terrace)

Tuesday, May 29, 2012

7:00 - 8:00 a.m.  Breakfast  (Riverview Lounge/ Ivor Petrak Lounge)

7:00 - 4:00 p.m.  Registration  (Curio Foyer)

8:00 a.m.  Opening Remarks - Gary Lopaschuk  (Alberta/ New Brunswick Room)
Organizer, ISHR NA Section 2012

8:15 - 9:00 a.m.  Plenary Talk:  (Alberta/ New Brunswick Room)
Eric Olson (University of Texas, Southwestern)
“Role of microRNA’s in heart failure”

9:00 - 12:00 p.m.  Morning Sessions 1 and 2  (Alberta/ New Brunswick Room)

10:20 – 10:40 a.m.  Coffee Break  (Riverview Lounge)
SESSION 1: 9:00 a.m. - Noon (Alberta Room)

Dynamics Of Mitochondria In Health And Disease
Chair: Ronglih Liao, Harvard Medical School

Ken Walsh, Boston University School of Medicine: “Role of mitofusions in mitochondrial form and function”

E. Dale Abel, Utah Diabetes Center: “Mechanisms for mitochondrial dysfunction in diabetic cardiomyopathy”

William Stanley, University of Maryland: “Dietary lipids impact mitochondrial phospholipid composition and permeability transition”

Rong Tian, University of Washington: “Mitochondrial dysfunction accelerates the development of heart failure”

Larry Young, Yale School of Medicine: “Role of macrophage migration inhibitory factor in ischemia reperfusion injury”

SESSION 2: 9:00 a.m. - Noon (New Brunswick Room)

Ubiquitin Proteosome System Inhibition as a Therapeutic Target in Cardiac Disease
Chair: Arzu Onay-Besikci, Ankara University

Monte Willis, University of North Carolina: “Role of the UPS in heart failure”

David C. Kem, University of Oklahoma Health Sciences Center: “Proteasome inhibition following ischemia prevents malignant ventricular tachyarrythmias and SCD in a model of myocardial infarction”

Heinrich Taegtmeyer, University of Texas: “Selling the family silver: AMPK regulates ubiquitin ligases in the starved heart”

Matthias Majetschak, Loyola University Chicago: “Regulation of the proteasome by ATP: Implications for ischemic myocardial injury and donor heart preservation”

Jeff Robbins, Cincinnati Children’s Medical Center: “Autophagy and proteotoxicity in cardiomyocytes”

Richard Kitsis, Albert Einstein College of Medicine: “Cell death in the pathogenesis of heart disease”

12:00 – 1:30 p.m. Lunch (Oak Room/Mt. Stephen Hall)

12:00 – 1:30 p.m. Poster Session I (Riverview Lounge)

12:00 - 1:00 p.m. ISHR Council Meeting (Norquay Room)

1:30 – 4:30 p.m. Young Investigator Competitions (Alberta/New Brunswick Room)
Chairs: Paul Simpson and Litsa Kranias

2:40 – 3:00 p.m. Coffee Break (Riverview Lounge)
Wednesday May 30, 2012

7:00 - 8:00 a.m.  Breakfast  (Cascade/ Conservatory)
7:00 – 4:00 p.m.  Registration  (Curio Foyer)
8:00 - 9:00 a.m.  Plenary Talk:  (Alberta/ New Brunswick Room)
Mark Sussman, San Diego State University
“Pim-1 kinase activation as a target for heart failure therapy”
9:00 - 12:00 p.m.  Morning Sessions 3 and 4  (Alberta/ New Brunswick Room)
10:20 – 10:40 a.m.  Coffee Break  (Riverview Lounge)

SESSION 3:  9:00 a.m. - Noon  (Alberta Room)

Targeting Novel Pathways As Potential Treatment For Human Heart Failure
Chair: Richard Schulz, University of Alberta

Gavin Y. Oudit, University of Alberta: “Enhancing ACE2 action in heart failure: novel role of Ang-1-7”
Emilio Hirsch, University of Torino: “Inhibition of PI3Kgamma signaling and heart disease”
Mark E. Anderson, University of Iowa: “CaMKII kinase inhibition: linking Ca^{2+} cycling dysregulation and ventricular arrhythmias”
Zam Kassiri, University of Alberta: “Preventing adverse remodeling of the ECM: role of TIMPs”
Francisco Villareal, UCSD: “Effects of epicatechin rich cocoa on skeletal muscle mitochondria, oxidative stress and sarcomere in heart failure patients”

SESSION 4:  9:00 a.m. – Noon  (New Brunswick Room)

Gender And Heart Failure
Chair: John McNeill, University of British Columbia

Andrea Dunaif, Northwestern University: “Androgenized and cardiometabolic risk in women”
Elizabeth Murphy, NIH, Bethesda: “Estrogen receptor activation and cardioprotection”
E. Douglas Lewandowski, University of Illinois at Chicago: “Sexual dimorphism in cardiac lipid dynamics”
Leslie A. Leinward, University of Colorado: “A woman is not a small man: sex differences in the cardiac myocyte”

Susan Howlett, Dalhousie University: “Gender and myocardial calcium handling”

12:00 – 1:30 p.m. Lunch (Cascade/ Conservatory)

12:00 – 1:30 p.m. Poster Session II (Riverview Lounge)

12:00 - 1:00 p.m. ISHR Council Meeting (Norquay Room)

1:30 – 4:30 p.m. Afternoon Sessions 5 and 6 (Alberta/ New Brunswick Room)

SESSION 5:  1:30 – 4:30 p.m. (Alberta Room)

Cardiac Signaling And Heart Failure
Chair: Naranjan Dhalla, University of Manitoba

Martin Young, University of Alabama at Birmingham: “Diurnal myocardial physiology and metabolism”

R. Daniel Rudic, Georgia Health Sciences University: “Circadian clocks in the cardiovascular system”

Michael Sole, University Health Network: “Diurnal physiology and the pathogenesis and treatment of cardiorenal disease”

Alex Zambon, University of California, San Diego: Role of hypoxia in the proliferation of cardiac progenitor cells

Michael Regnier, University of Washington: “Elevating cellular 2 deoxy-ATP to increase myocardial performance”

Jeff Karpen, University of California, San Diego: “Cellular dynamics of second messengers in cardiac myocytes”

SESSION 6:  1:30 – 4:30 p.m. (New Brunswick Room)

Energy Metabolism In The Failing Heart
Chair: Said Khatib, Jordan University of Science and Technology

Ira Goldberg, New York Presbyterian Hospital: “Lipotoxicity in the heart failure”

Jason Dyck, University of Alberta: “Fatty acid handling in the failing heart”

Dan Kelly, Sanford/ Burnham Medical Research Institute: “Mitochondrial dysfunction and heart failure”

Gary Lopaschuk, University of Alberta: “Metabolic modulators as therapy for heart failure/dilated cardiomyopathy”
Yibin Wang, University of California, Los Angeles: “Branched chain amino acid metabolism in heart failure”

Cliff Folmes, Mayo Clinic, Rochester: “Stem cell energetics”

4:30 – 5:30 p.m. Reception and Poster Session II (Riverview Lounge)

7:00 p.m. Cocktail Reception (Riverview Lounge)

7:30 p.m. Banquet (Alberta/ New Brunswick Room)

Thursday May 31, 2012

7:00 - 8:00 a.m. Breakfast (Riverview Lounge)

8:00 - 8:15 a.m. Closing Remarks - Gary Lopaschuk Organizer, ISHR NA Section 2012 (Alberta/ New Brunswick Room)

8:15 - 9:00 a.m. The Pfeiffer Distinguished Lecture 2012 (Alberta/ New Brunswick Room)
Daria Mochly-Rosen, Stanford University
“Crossing the valley of death - drug discovery for heart disease in academia”

9:00 - 12:00 p.m. Morning Sessions 7 and 8 (Alberta/ New Brunswick Room)

10:20 - 10:40 a.m. Coffee Break (Riverview Lounge)

SESSION 7: 9:00 a.m. – Noon (Alberta Room)

Novel Therapies For Human Heart Failure
Chair: Terje Larsen, University of Tromso (Norway)

Stephan F. Vatner, University of Medicine and Dentistry of New Jersey: “Myosin activators and inhibitors as novel therapies for heart failure”

Richard Schulz, University of Alberta: “Inhibiting matrix metalloproteinase decreases intracellular proteolytic stress in the failing heart”

John Seubert, University of Alberta: “Targeting eicosanoids for cardioprotection”

Ernst Schwarz, Cedars Sinai Heart Institute: “The potential effects of IGF-1 and GH on patients with chronic heart failure”

Art Feldman, Temple University: “Role of vasopressin in receptor modulation in heart failure”
SESSON 8:  9:00 a.m. – Noon  (New Brunswick Room)

Proteomic In Heart Failure
Chair: Tom Scholz, University of Iowa

Anthony Gramolini, University of Toronto: “Large scale proteomic analysis of heart failure”

Peipei Ping, University of California, Los Angeles: “Cardiac Proteasomes in health and disease”

Jennifer Van Eyk, John Hopkins University: “Heart failure, myofilament and post translational modifications”

Thomas Kislinger, University of Toronto: “Plasma membrane enrichments of cardiovascular relevant cells”

Tom Vondriska, University of California, Los Angeles: “Protein determinant of chromatin structure and function in heart failure”